Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Lo, David K H ^a   Hurley, Matthew N ^a   Muhlebach, Marianne S ^b   Smyth, Alan R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIUM COLONY; BACTERIUM ISOLATION; BODY MASS; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CYSTIC FIBROSIS; DRUG USE; ERADICATION THERAPY; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE COST; HUMAN; LUNG FUNCTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NONHUMAN; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; DRUG EFFECT; MICROBIOLOGY; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84875506513     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009650.pub2     Document Type: Review

References (89)

1. Adeboyeku DU, Agent P, Jackson V, Hodson M. A double blind randomised study to compare the safety and tolerance of differing concentrations of nebulised colistin administered using HaloLite in cystic fibrosis (CF) patients [abstract]. Pediatric Pulmonology 2001;32(S22):288.
2. Amelina E, Senkevich N, Cherniak A, Cherniaev A, Chuchalin A. Home intravenous therapy in adult cystic fibrosis patients. The impact on lung function and quality of life [abstract]. European Respiratory Journal 2000;16 Suppl 31:123s.
3. Carswell F, Ward C, Cook DA, Speller DC. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. British Journal of Diseases of the Chest 1987;81(4):356-60.
4. Chua H, Collis G, Souef P. Bronchial response of children with cystic fibrosis to nebulised antibiotics [abstract]. Australian and New Zealand Journal of Medicine 1990;20:537.
5. Chua HL, Collis GG, Le Souef PN. Bronchial response to nebulized antibiotics in children with cystic fibrosis. European Respiratory Journal 1990;3(10):1114-6.
6. Conway SP. Ceftazidime 3G BD is as effective as ceftazidime 2G TDS in the treatment of respiratory exacerbations in cystic fibrosis [abstract]. Israel Journal of Medical Sciences 1996;32 Suppl:S256.
7. Cooper DM, Harris M, Mitchell I. Comparison of intravenous and inhalation antibiotic therapy in acute pulmonary deterioration in cystic fibrosis [abstract]. American Review of Respiratory Disease 1985;131:A242.
8. David RL, Koup JR, Williams Warren J, Weber A, Heggen J, Stempel D, Smith AL. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrobial Agents and Chemotherapy 1987;31(6):915-9.
9. Degg C, Mulheran M. The effect of frequent exposure to gentamicin on distortion product OAEs in patients with cystic fibrosis. British Journal of Audiology 1996;30(2):99-100.
10. Dodd M, Maddison J, Abbott J, Webb AK. The effect of the tonicity of nebulised colistin on lung function in adults with cystic fibrosis [abstract]. Proceedings of 18th European Cystic Fibrosis Conference; 1993 May 21-26; Madrid, Spain. 1993:121.
11. Dodd ME, Maddison J, Abbot J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with Cystic Fibrosis. Thorax 1997;52(7):656-8.
12. Dodd ME, Maddison J, Abbot J, Webb AR. The effect of the tonicity of nebulised colistin on chest tightness and lung function in adults with cystic fibrosis [abstract]. European Respiratory Journal 1993;6 Suppl 17:515s.
13. Dodd ME, Haworth CS, Moorcroft AJ, Miles J, Webb AK. Is medicine evidence-based when there is discrepancy between patient reported and objective measures of compliance in clinical trials? [abstract]. Pediatric Pulmonology 1998;26(S17):389-90.
14. Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, et al.Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcusaureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. Journal of Hospital Infection 2004;56(3):208-14.
15. Geller DE, Rodriguez CA, Howenstine M, Murphy T, Voter K, Nickerson B, et al.The effects of doubling concentration of tobramycin solution for inhalation on pharmacokinetics (PK), safety and delivery time in patients with cystic fibrosis (CF) [abstract]. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A391.
16. Rosenfeld M, Geller DE, Rodriguez CA, Howenstine M, Konstan M, Ordonez C, et al.Serum pharmacokinetics of two preparations of tobramycin solution for inhalation in young cystic fibrosis patients [abstract]. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A386.
17. Goldfarb J, Wormser GP, Inchiosa MA Jr, Guideri G, Diaz M, Gandhi R, et al.Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. Journal of Clinical Pharmacology 1986;26(3):222-6.
18. Geller DE, Flume P, Schwab R, Fornos P, Conrad DJ, Morgan E, et al.A phase 1 safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients [abstract]. Pediatric Pulmonology 2008;43 Suppl 31:315.
19. Griffith DC, Hansen C, Pressler T, Balchen T, Jensen TJ, Geller DE, et al.Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications [abstract]. Journal of Cystic Fibrosis 2008;7 Suppl 2:S26.
20. Gulliver T, Wilson S, Williams G, Harris M, Cooper D. Nebulized tobramycin (intravenous solution) is tolerated without inducing cough and wheeze in cystic fibrosis patients [abstract]. Proceedings of the Thoracic Society of Australia & New Zealand Annual Scientific Meeting; 2003 April 4-9; Adelaide, Australia. 2003:A139.
21. Heininger U, Bowing B, Stehr K, Solbach W. Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration. Klinische Padiatrie 1993;205(1):18-22.
22. Hjelte L, Widen B, Malmborg AS, Freyschuss U, Strandvik B. Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life. Lakartidningen 1988;85(18):1614-7.
23. Huang N, Palmer J, Schidlow D, Hsuan F, Hsu C, Goldberg M, et al.Evaluation of antibiotic therapy in patients with cystic fibrosis. Chest 1979;76(3):354-5.
24. App EM, Huls G, Bittner-Dersch P, Stolz S, Lindemann H, Matthys H. Impaired lung function influences the serum concentration of inhaled drugs in cystic fibrosis [abstract]. Pediatric Pulmonology 2000;30(S20):279-80.
25. Huls G, App EM, Bittner-Dersch P, Stolz S, Lindemann H. Impaired lung function influences the serum concentration of inhaled drugs in cystic fibrosis [abstract]. Proceedings of 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:177.
26. Junge S, Kruger K, Schonweiler R, Ptok M, Ballmann M. Once daily dosage of intravenous tobramycin - increased risk for cochlea damage in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2001;32(S22):291.
27. Kruger K, Junge S, Schonweiler R, Ptok M, Ballmann M. Once daily dosage of intravenous tobramycin in patients with cystic fibrosis - increased risk for cochlea damage? [abstract]. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P191.
28. Kapranov NI, Belousov YB, Kashyrskaya NY, Smirnova EY. Quinoline therapy in children with cystic fibrosis [abstract]. Proceedings of 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:P19.
29. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al.Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2011;55(7):3393-8.
30. Coates AL, Denk O, Leung K, Ribeiro N, Chan J, Green M, et al.Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatric Pulmonology 2011;46(4):401-8. [CFGD CF Register: PI241b]
31. Keller M, Coates AL, Griese M, Denk O, Schierholz J, Knoch M. In-vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150mg/1.5ml) administered by the eFlow® electronic nebuliser compared to TOBI® in the PARI LC PLUS® [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S22.
32. Knight RK, Batten JC, Mearns M. A double blind trial of cephalexin in cystic fibrosis patients with pseudomonas in the sputum [abstract]. Proceedings of 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:52.
33. Labiris R, Freitag A, Pratt B, Efthimiadis A, Hargreave F, Dolovich M. Does inhalation of preservatives from IV tobramycin preparations (TOB) cause airway inflammation? [abstract]. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A307.
34. Loening Baucke VA, Mischler E, Myers MG. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. Journal of Pediatrics 1979;95(4):630-7.
35. Loening-Baucke VA, Mischler EH, Myers MG. Cephalexin in cystic fibrosis: a placebo-controlled study [abstract]. Pediatric Research 1978;12(4 Pt 2):495.
36. Loening-Bauke, Mischler EH, Myers MG. Cephalexin compared to placebo in the management of patients with cystic fibrosis. Proceedings of 19th Cystic Fibrosis Club Abstracts; 1978. 1978:69.
37. Macfarlane M, Leavy A, McCaughan J, Fair R, Reid AJM. Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. Journal of Hospital Infection 2007;65(3):231-6.
38. Maiz L, Canton R, Mir N, Baquero F, Escobar H. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatric Pulmonology 1998;26(4):287-9.
39. Nathanson I, Cropp GJA, Li P, Neter E. Effectiveness of aerosolized gentamicin in cystic fibrosis (CF) [abstract]. Cystic Fibrosis Club Abstracts; 1985. 1985:145.
40. Nolan G, McIvor P, Levison H, Fleming PC, Corey M, Gold R. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. Journal of Pediatrics 1982;101(4):626-30.
41. Pai MP, Allen SE, Amsden GW. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. Journal of Cystic Fibrosis 2006;5(3):153-7.
42. Postnikov SS, Semykin SI, Kapranov NI, Perederko LV, Polikarpova SV, Khamidullina KF. Evaluation of tolerance and efficacy of pefloxacin in the treatment and prevention of severe infections in children with mucoviscidosis and aplastic anemia. Antibiotiki i Khimioterapiia 2000;45(8):25-30.
43. Postnikov SS, Semykin SJ, Najimov VP. Safety of fluoroquinolones in children [abstract]. Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P213.
44. Postnikov SS, Semiakin SI, Nazhimov VP, Kapranov NI. Comparative yearly growth rate of children with mucoviscidosis treated and not treated with ciprofloxacin: clinicomorphological comparisons. Antibiotiki I Khimioterapiia 2001;46(10):11-3.
45. Ramstrom H, Erwander I, Mared L, Kornfalt R, Seiving B. Pharmaceutical intervention in the care of cystic fibrosis patients. Journal of Clinical Pharmacy and Therapeutics 2000;25(6):427-34.
46. Roberts GW, Nation RL, Jarvinen AO. Measurement of serum tobramycin in the presence of ticarcillin or piperacillin. Australian Journal of Hospital Pharmacy 1992;22(2):152-4.
47. Roberts GW, Nation RL, Jarvinen AO, Martin AJ. An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients. British Journal of Clinical Pharmacology 1993;36:372-5.
48. Romano L, Girosi D, Spallone E, Parisi F, Minicucci L, Romano C. The use of ofloxacin in cystic fibrosis patients. Minerva Pediatrica 1992;44(3):79-86.
49. Romano L, Minicucci L, Spallone E, Girosi D, Campelli A, Fabbri A, et al.Role of home therapy with ofloxacin in patients with cystic fibrosis (CF). Giornale Italiano de Chemioterapia 1991;38(1-3):181-3.
50. Rosenfeld M, Emerson J, Uh D, Anderson G, Genatossio A, McNamara S, et al.Does tobramycin accumulate in respiratory secretions with repeated aerosol administration: a pilot study [abstract]. Pediatric Pulmonology 2006;41(S29):327.
51. Salh B, Bilton D, Dodd M, Abbot J, Webb K. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scandinavian Journal of Infectious Diseases 1992;24(2):215-8.
52. Shapera RM, Warwick WJ, Matsen JM. Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis. Journal of Pediatrics 1981;99(4):647-50.
53. Smith A, Weber A, Pandher R, Williams-Warren J, Cohen MJ, Ramsey B. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Infection 1997;25(2):106-8.
54. Solís A, Brown D, Hughes J, Van Saene HK, Heaf DP. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatric Pulmonology 2003;36(3):189-95.
55. Shalit I, Stutman HR, Marks MI, Chartrand SA, Hilman BC. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4A):189-95.
56. Stutman HR, Shalit I, Marks MI, Greenwood R, Chartrand SA, Hillman BC. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. American Journal of Medicine 1987;82(Suppl 4A):142-5.
57. Vitti TG, Berg TJ, Pagtakhan RD. The effect of pancreatic enzyme supplement on the intestinal absorption of ampicillin and cloxacillin in children with cystic fibrosis [abstract]. 16th Cystic Fibrosis Club Abstracts. 1975:56.
58. Wood PJ, Ioannides Demos LL, Li SC, Williams TJ, Hickey B, et al.Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996;51(4):369-73.
59. Persistent methicillin-resistant Staphylococcus aureus eradication protocol. Ongoing study Oct 2012.
60. Early methicillin-resistant Staphylococcus aureus (MRSA) therapy in cystic fibrosis (CF). Ongoing study April 2011.
61. Cystic Fibrosis Foundation. Patient Registry. 2009 Annual Data Report, Bethesda, Maryland 2009.
62. Cystic Fibrosis Foundation. Patient Registry. 2010 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation, 2010.
63. UK Cystic Fibrosis Trust. Methicillin-resistant Staphylococcus aureus (MRSA). A report of the UK Cystic Fibrosis Trust Infection Control Working Group 2008.
64. Cystic Fibrosis Trust. UK CF Registry. Annual Data Report 2009.
65. CF Trust. What is cystic fibrosis?. www.cftrust.org.uk/aboutcf/whatiscf/ (accessed 04 August 2011).
66. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Reviews Microbiology 2009;7(9):629-41.
67. Cystic Fibrosis Australia. Cystic Fibrosis in Australia 2009. 12th Annual Report from the Australian Cystic Fibrosis Data Registry 2011.
68. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent Methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2008;178(8):814-21.
69. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010;303(23):2386-92.
70. Deeks J, Higgins J, Altman D. Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
71. Doe SJ, McSorley A, Isalska B, Kearns AM, Bright-Thomas R, Brennan AL, et al.Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. Journal of Cystic Fibrosis 2010;9(2):104-9.
72. European Centre for Disease Prevention and Control. Proportion of methicillin-resistant Staphylococcus aureus (MRSA) isolates in participating countries in 2009. http://ecdc.europa.eu/EN/ACTIVITIES/SURVEILLANCE/EARS-NET/DATABASE/Pages/map_reports.aspx (accessed 04 August 2011).
73. Elizur A, Orscheln RC, Ferkol TW, Atkinson JJ, Dunne WM, Buller RS, et al.Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 2007;131(6):1718-25.
74. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al.Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine 2007;176(10):957-69.
75. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
76. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
77. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
78. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, et al.Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010;304(6):641-9.
79. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R, et al.Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clinical Infectious Diseases 2006;42(3):389-91.
80. Liebowitz LD. MRSA burden and interventions. International Journal of Antimicrobial Agents 2009;34 Suppl 3:S11-S13.
81. Loeb MB, Main C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD003340]
82. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, et al.Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the US and Canada. Pediatric Pulmonology 1999;28(4):231-41.
83. Muhlebach MS, Miller M, LaVange LM, Mayhew G, Goodrich JS, Miller MB. Treatment intensity and characteristics of MRSA infection in CF. Journal of Cystic Fibrosis 2011;10(3):201-6.
84. Pearson A, Chronias A, Murray M. Voluntary and mandatory surveillance for methicillin-resistant Stapylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) bacteraemia in England. Journal of Antimicrobial Chemotherapy 2009;64 Suppl 1:i11-i17.
85. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
86. Ren CL, Morgan WJ, Konstan MW, Schechter MS, Wagener JS, Fisher KA, et al.Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatric Pulmonology 2007;42(6):513-8.
87. Sawicki GS, Rasouliyan L, Pasta DJ, Regelmann WE, Wagener JS, Waltz DA, et al.The impact of incident methicillin-resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatric Pulmonology 2008;43(11):1117-23.
88. Smyth AR, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD001912]
89. Vanderhelst E, De Meirleir L, Verbanck S, Pierard D, Vincken W, Malfroot A. Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients. Journal of Cystic Fibrosis 2012; Vol. 11, issue 1:2-7.